Trials / Unknown
UnknownNCT03815630
A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors
Clinical Study on the Safety and Efficacy of Pd-1 Combined With Dc-cik in the Treatment of Solid Tumors
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Allife Medical Science and Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This is a single center、single arm、open-label, to investigate the safety and efficacy of PD-1 and DC-CIK with anti-solid tumor
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pd-1 and dc-cik cells | Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 . |
Timeline
- Start date
- 2019-02-01
- Primary completion
- 2020-02-01
- Completion
- 2021-02-01
- First posted
- 2019-01-24
- Last updated
- 2019-01-30
Source: ClinicalTrials.gov record NCT03815630. Inclusion in this directory is not an endorsement.